How many shares did Vertex repurchase in the first half of 2026?

Vertex repurchased approximately 0.7 million shares in the six-month period ending June 30, 2026, as evidenced by the decline in common shares outstanding from 254.0 million at year-end 2025 to 253.3 million at mid-year 2026. The specific execution price and total dollar amount are not disclosed in this earnings announcement.

What was the authorization amount for Vertex's share repurchase program?

The filing does not disclose the dollar authorization amount, expiration date, or remaining authorization for Vertex's share repurchase program. This Q2 2026 earnings release only confirms that the company is executing repurchases 'pursuant to its share repurchase program' without providing the underlying program details.

Did share repurchases reduce Vertex's cash balance?

No. Despite repurchasing shares, Vertex's cash, cash equivalents, and marketable securities grew from $12.3 billion at year-end 2025 to $13.6 billion at June 30, 2026. The company's strong operational cash generation more than offset the capital deployed for buybacks, resulting in a net increase in liquidity.

Why might Vertex slow down or modify buyback activity going forward?

Vertex is pursuing the $10 billion acquisition of Crinetics Pharmaceuticals, expected to close in Q3 2026. The pending transaction may influence near-term repurchase strategy as management prioritizes balance-sheet capacity and uses of cash for the M&A integration. Management has indicated it will provide updated guidance after the transaction closes.

How do Vertex's buybacks relate to stock-based compensation?

Vertex's stock-based compensation expense was $170.2 million in Q2 2026 (and $336.6 million in the first half). The modest share count reduction of 0.7 million over six months suggests buybacks are offsetting only a portion of dilution from equity grants, which increased shares outstanding by larger amounts than repurchases retired.

VRTX 8-K Filed 2026-08-03 Execution disclosure

Vertex repurchased shares under buyback program in Q2 2026

Pharmaceutical firm continued stock repurchases; cash position increased to $13.6B despite buyback activity

MechanismNot specified

What the filing says

Vertex Pharmaceuticals reported in its second quarter 2026 earnings filing that the company continued to repurchase shares under its share repurchase program during the period. The filing notes that cash, cash equivalents, and total marketable securities increased to $13.6 billion as of June 30, 2026, compared to $12.3 billion as of December 31, 2025. Management explicitly stated that this increase was "primarily due to cash flows from operating activities, partially offset by repurchases of Vertex's common stock pursuant to its share repurchase program."

The filing documents that common shares outstanding declined from 254.0 million at December 31, 2025, to 253.3 million at June 30, 2026, representing 0.7 million shares retired through buyback activity over the six-month period. However, the specific dollar amount expended, average repurchase price per share, and the authorization details are not disclosed in this earnings announcement. The company's strong operational cash generation in the first half of 2026 enabled simultaneous execution of share repurchases while expanding the cash position.

700000

Cash, cash equivalents, and total marketable securities as of June 30, 2026, were $13.6 billion, compared to $12.3 billion as of December 31, 2025. The increase was primarily due to cash flows from operating activities, partially offset by repurchases of Vertex's common stock pursuant to its share repurchase program. — VERTEX PHARMACEUTICALS INC / MA 8-K filing · View on SEC EDGAR →

What this means

Vertex's disclosure of ongoing share repurchases confirms the company is executing a previously authorized buyback program, though specific authorization terms and execution details are absent from this earnings filing. The modest decline in shares outstanding (0.7 million shares, or approximately 0.3% of the base) over six months suggests measured repurchase activity, potentially executed under a Rule 10b-18 open-market framework. The fact that cash balances grew despite repurchases underscores robust operational cash generation—Q2 2026 net income reached $1.1 billion GAAP and $1.2 billion non-GAAP—allowing the company to return capital via buybacks while maintaining financial flexibility for the pending $10 billion Crinetics acquisition. Share count reduction partially offsets dilution from stock-based compensation, which totaled $170.2 million in Q2.

Frequently asked questions

How many shares did Vertex repurchase in the first half of 2026?: Vertex repurchased approximately 0.7 million shares in the six-month period ending June 30, 2026, as evidenced by the decline in common shares outstanding from 254.0 million at year-end 2025 to 253.3 million at mid-year 2026. The specific execution price and total dollar amount are not disclosed in this earnings announcement.
What was the authorization amount for Vertex's share repurchase program?: The filing does not disclose the dollar authorization amount, expiration date, or remaining authorization for Vertex's share repurchase program. This Q2 2026 earnings release only confirms that the company is executing repurchases 'pursuant to its share repurchase program' without providing the underlying program details.
Did share repurchases reduce Vertex's cash balance?: No. Despite repurchasing shares, Vertex's cash, cash equivalents, and marketable securities grew from $12.3 billion at year-end 2025 to $13.6 billion at June 30, 2026. The company's strong operational cash generation more than offset the capital deployed for buybacks, resulting in a net increase in liquidity.
Why might Vertex slow down or modify buyback activity going forward?: Vertex is pursuing the $10 billion acquisition of Crinetics Pharmaceuticals, expected to close in Q3 2026. The pending transaction may influence near-term repurchase strategy as management prioritizes balance-sheet capacity and uses of cash for the M&A integration. Management has indicated it will provide updated guidance after the transaction closes.
How do Vertex's buybacks relate to stock-based compensation?: Vertex's stock-based compensation expense was $170.2 million in Q2 2026 (and $336.6 million in the first half). The modest share count reduction of 0.7 million over six months suggests buybacks are offsetting only a portion of dilution from equity grants, which increased shares outstanding by larger amounts than repurchases retired.

execution pharma-sector q2-2026 rule-10b-18

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.